Angiotensin II, From Vasoconstrictor to Growth Factor
2014; Lippincott Williams & Wilkins; Volume: 114; Issue: 5 Linguagem: Inglês
10.1161/circresaha.114.303045
ISSN1524-4571
AutoresS. Vukelic, Kathy K. Griendling,
Tópico(s)Hormonal Regulation and Hypertension
ResumoHomeCirculation ResearchVol. 114, No. 5Angiotensin II, From Vasoconstrictor to Growth Factor Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBAngiotensin II, From Vasoconstrictor to Growth FactorA Paradigm Shift Sasa Vukelic and Kathy K. Griendling Sasa VukelicSasa Vukelic From the Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA. and Kathy K. GriendlingKathy K. Griendling From the Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA. Originally published28 Feb 2014https://doi.org/10.1161/CIRCRESAHA.114.303045Circulation Research. 2014;114:754–757IntroductionAngiotensin II (Ang II) is today considered as one of the essential factors in the pathophysiology of cardiovascular disease, producing acute hemodynamic and chronic pleiotropic effects. Although now it is widely accepted that these chronic effects are important, Ang II was initially considered only a short-acting, vasoactive hormone. This view was modified a quarter of a century ago when Dr Owens and his group published an article in Circulation Research with initial evidence that Ang II can act as a growth factor that regulates cell hypertrophy. They showed in a series of elegant experiments that Ang II promotes hypertrophy and hyperploidy of cultured rat aortic smooth muscle cells. However, Ang II had no effect on hyperplasia. These findings led to a paradigm shift in our understanding of the roles of growth factors and vasoactive substances in cardiovascular pathology and helped to redirect basic and clinical renin–angiotensin system research during the next 25 years. Ang II is now known to be a pleiotropic hormone that uses multiple signaling pathways to influence most processes that contribute to the development and progression of cardiovascular diseases, ranging from hypertrophy, endothelial dysfunction, cardiac remodeling, fibrosis, and inflammation to oxidative stress.The renin–angiotensin system (RAS) is now considered one of the essential factors in the pathophysiology of cardiovascular disease. The main effector of the RAS, angiotensin II (Ang II), contributes to the development of cardiovascular disease as both an endocrine and a local autocrine/paracrine hormone, producing acute (vasoconstriction, water/salt retention) and more importantly chronic (hypertrophy, hyperplasia, oxidative stress, fibrosis, and inflammation) effects. Today, it is widely accepted that these chronic effects have a critical role in the development and progression of cardiovascular diseases, such as hypertension, atherosclerosis, and heart failure. Initially, Ang II was considered predominantly as a short-acting, vasoactive hormone, and its role in the pathology of cardiovascular disease was thought to result from acute hemodynamic changes. This view was modified a quarter of a century ago when Dr Owens and his group published an article in Circulation Research with initial evidence that Ang II can act as a growth factor that regulates cell hypertrophy.1 This article completely changed our perspective on both the pathophysiology of cardiovascular diseases and the critical contribution of Ang II to them, and this is the focus of the current commentary.Research on Ang II as a central component of the RAS began more than a century ago in 1898 with studies performed by Scandinavian researchers.2 They reported a vasoconstrictor effect of a substance from renal extracts, which they subsequently named renin based on its origin. Interest in the nature of this vasoactive substance released by the kidney was renewed in 1934 when Goldblatt et al3 demonstrated that clamping dog renal arteries produced chronic hypertension. In the late 1930s, 2 independent groups in Argentina and the United States used the Goldblatt renal ischemia technique to demonstrate secretion of a pressor agent with effects similar to renin.4,5 This short-acting vasoconstrictor was later identified as an octapeptide product of renin and named Ang.6 During the next half-century, a tremendous amount of research was performed describing in detail the interdependence of the RAS components and the mechanism of action of Ang II, the primary effector molecule of this system.7Up to this point, research efforts were mainly focused on the role of Ang II as an acute regulator of vasomotor tone. The first Food and Drug Administration–approved angiotensin-converting enzyme (ACE) inhibitor, captopril, was developed for the treatment of essential hypertension in 1977,8 based on early experimental data on the effect of Ang II on blood pressure in hypertension and chronic heart failure.9 ACE inhibitors proved to be clinically successful in reducing symptoms of hypertension and heart failure,10 despite the fact that there was no experimental evidence indicating that the inhibition of Ang II synthesis is more beneficial than other modalities of antihypertensive therapy. Interestingly, Dr Owens' group was later one of the first to notice a difference in effects between classes of antihypertensive medications.11 However, at that time the RAS was still considered to be an endocrine system in which Ang II had a central role as a potent, short-acting pressor. Furthermore, because of an unfavorable side effect profile of early ACE inhibitors, they were not initially considered as a first choice medication in the treatment of hypertension.12The dynamics of both basic and clinical RAS research changed in the late 1980s when evidence first emerged that Ang II can function as a local autocrine and paracrine factor regulating growth of components of the cardiovascular system. Dr Owens' seminal article was the first to show the direct growth effect of Ang II in vascular smooth muscle cells (VSMCs).1 In this article, based on his group's previous findings of the correlation between hypertension and VSMC hypertrophy,13 as well as the differential effectiveness of various antihypertensive drugs on the reversal of hypertrophy,11 he postulated that chronic treatment with a contractile agonist such as Ang II can induce hypertrophy of VSMCs. In a series of elegant experiments, the authors proved without doubt that Ang II is an extremely potent inducer of receptor-dependent hypertrophy in VSMCs. This effect was accompanied by the development of hyperploidy, but not hyperplasia, and was fully reversible with a specific Ang II antagonist. Dr Owens' group later confirmed these cell culture–based results in tissues.14These findings helped to redirect basic and clinical RAS research. Ang II is now known to be a pleiotropic hormone that can influence virtually every process necessary for the development and progression of cardiovascular diseases ranging from hypertension, atherosclerosis, restenosis, and chronic kidney disease to heart failure (Figure). Chronic Ang II exposure promotes hypertrophy of VSMCs, phenotype modulation and differentiation, endothelial dysfunction, cardiac remodeling, fibrosis, inflammation, and oxidative stress.1,15 Dr Owens' research efforts in later years showed that Ang II, in addition to hypertrophy, may play an important role in a regulation of differentiation and phenotype switching in VSMCs.16 His group has critically contributed to our understanding of the molecular regulation of expression of VSMC marker genes.17–19Download figureDownload PowerPointFigure. Paradigm shift in Angiotensin research: From vasoactive, short-acting hormone to pleiotropic growth factor and immunomodulator. Dr Owens' findings that Angiotensin II (Ang II) is not just an acute vasoactive substance but also a potent growth factor inspired multiple new studies in different basic research fields from inflammation to tyrosine kinase signaling. These basic research results served as a starting point for clinical research studies that caused a change in therapeutic practices, with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) becoming cornerstone of therapy. ATR1 indicates angiotensin II receptor, type 1; JAK, janus kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEKK, MAP kinase kinase kinase; NO, nitric oxide; NOX, nicotinamide adenine dinucleotide phosphatase oxidase; PI3K, phosphatidylinositol 3-kinases; PKC, protein kinase C; STAT, signal transducers and activators of transcription; and VSMC, vascular smooth muscle cell.Once the vasoactive agonist Ang II was established as growth factor, the converse was also described. Platelet-derived growth factor and epidermal growth factor were found to be vasoconstrictors, suggesting that growth factors and vasoconstrictors shared signaling.20,21 Similarly, other vasoactive factors, such as thrombin, were shown to have mitogenic effects on VSMCs.22These novel findings changed the approach to understanding receptor-mediated signaling pathways. Because initially Ang II was considered to be a predominantly vasoactive hormone, in the 1980s, the majority of signaling research was focused on the stimulation of phospholipase C and Ca2+ mobilization via G protein–coupled receptors, as well as activation of phospholipase D and protein kinase C and their effect on smooth muscle contraction.15 However, when Dr Owens' article described the prohypertrophic effects of Ang II, basic research in the 1990s shifted to studying the activation of tyrosine kinases, transactivation of receptor tyrosine kinases, and activation of nicotinamide adenine dinucleotide phosphatase oxidases (Figure). In one of the earliest reports, Tsuda et al23 demonstrated that vasoconstrictors such as Ang II can specifically stimulate the tyrosine phosphorylation of multiple proteins in vascular smooth muscle cells. This early success sparked research efforts that identified numerous additional tyrosine-phosphorylated proteins. Of special significance was the discovery of Ang II–induced transactivation of receptor tyrosine kinases (epidermal growth factor, platelet-derived growth factor, insulin receptor) and nonreceptor tyrosine kinases (c-Src family kinases, focal adhesion kinase, and Janus kinases) leading to phosphorylation and modulation of activity of multiple downstream targets such as mitogen-activated protein kinases (summarized in the work by Mehta and Griendling15). Another important line of research that followed was the signaling mediated by activation of the nicotinamide adenine dinucleotide phosphatase oxidases and reactive oxygen species synthesis.24 Ang II was initially considered a nonspecific, potent mediator of oxidative stress but was later shown to use reactive oxygen species as specific second messengers that mediate signaling in different pathways that can contribute to the development of cardiovascular diseases. Ang II was shown to mediate VSMC growth, differentiation, migration, fibrosis, and remodeling as a basis of its physiological and pathological roles (Figure).These findings led to a shift in clinical research and ultimately therapeutic approaches. In the 1980s, the focus of clinical research was on the hemodynamic effects of ACE inhibitor therapy25 and its correlation with symptomatic improvement in congestive heart failure and hypertension.26 In the 1990s, after publication of Dr Owens' study and based on new basic science findings of the pleiotropic effects of chronic Ang II stimulation beyond its acute hemodynamic effects, the focus of clinical studies changed to the effect of ACE inhibitors on mortality. This is an example of translational research at best. Dr Owens' article created a paradigm shift in our understanding of the role of Ang II in cardiovascular pathology and inspired multiple new basic research studies that served as a starting point for further clinical research. Subsequently, ACE inhibitors were shown to promote survival of patients with congestive heart failure, myocardial infarction, coronary artery disease, and hypertension.27–29 It also became clear that they have a renoprotective effect independent of their effects on blood pressure.30 These results confirmed hypothesis originating from basic research that ACE inhibitors, in comparison with other classes of antihypertensive medications, have pleiotropic, disease-modifying effects beyond decreasing blood pressure. This triggered a complete change in therapeutic approaches. Consequently, ACE inhibitors and Ang II receptor blockers have become an indispensable and primary component of cardiovascular disease treatment.31–33To mark the 60th birthday of Circulation Research (1953-2013), the editors have commissioned Circulation Research Classics, a series of commentaries highlighting seminal articles published in the journal over the past six decades that have importantly shaped cardiovascular research. Written by leading experts, Circulation Research Classics are intended to describe the impact of these articles on the field by putting them in a historical perspective. The concept of "classic" is inextricably linked to time—a classic is something that maintains its value regardless of its age. Thus, an important consideration in selecting the articles to be highlighted is that they have stood the test of time, which is the most reliable indicator of the value of scientific work. By looking back at the illustrious past of Circulation Research, we hope to promote a deeper appreciation of the contributions of this journal to the advancement of knowledge.Sources of FundingThis work is supported by National Institutes of Health grants HL38206, HL095070, and HL058863.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Kathy K. Griendling, PhD, Emory University, Division of Cardiology, 101 Woodruff Circle, WMB 308, Atlanta, GA 30322. E-mail [email protected]References1. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.Circ Res. 1988; 62:749–756.LinkGoogle Scholar2. Tigerstedt R, Bergman PQ. Niere und kreislauf1.Skandinavisches Archiv Für Physiologie. 1898; 8:223–271.CrossrefGoogle Scholar3. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia.J Exp Med. 1934; 59:347–379.CrossrefMedlineGoogle Scholar4. Fasciolo JC, Leloir LF, Muñoz JM, Braun-Menendez E. On the specificity of renin.Science. 1940; 92:554–555.CrossrefMedlineGoogle Scholar5. Page IH, Helmer OM, Kohlstaedt KG, Fouts PJ, Kempf GF. Reduction of arterial blood pressure of hypertensive patients and animals with extracts of kidneys.J Exp Med. 1941; 73:7–41.CrossrefMedlineGoogle Scholar6. Braun-Menendez E, Page IH. Suggested Revision of Nomenclature–Angiotensin.Science. 1958; 127:242.CrossrefMedlineGoogle Scholar7. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.J Manag Care Pharm. 2007; 13:9–20.CrossrefMedlineGoogle Scholar8. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.Science. 1977; 196:441–444.CrossrefMedlineGoogle Scholar9. Gavras H, Flessas A, Ryan TJ, Brunner HR, Faxon DP, Gavras I. Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension.JAMA. 1977; 238:880–882.CrossrefMedlineGoogle Scholar10. Corea L, Bentivoglio M, Verdecchia P. Low-dose captopril therapy in mild and moderate hypertension. Randomized comparison of twice daily vs three times daily doses.Hypertension. 1983; 5:III157–159.LinkGoogle Scholar11. Owens GK. Differential effects of antihypertensive drug therapy on vascular smooth muscle cell hypertrophy, hyperploidy, and hyperplasia in the spontaneously hypertensive rat.Circ Res. 1985; 56:525–536.LinkGoogle Scholar12. Borer JS. Angiotensin-converting enzyme inhibition: A landmark advance in treatment for cardiovascular diseases.Eur Heart J. Suppl. 2007; 9:E2–E9.CrossrefGoogle Scholar13. Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats.Hypertension. 1987; 9:178–187.LinkGoogle Scholar14. Holycross BJ, Peach MJ, Owens GK. Angiotensin II stimulates increased protein synthesis, not increased DNA synthesis, in intact rat aortic segments, in vitro.J Vasc Res. 1993; 30:80–86.CrossrefMedlineGoogle Scholar15. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system.Am J Physiol Cell Physiol. 2007; 292:C82–C97.CrossrefMedlineGoogle Scholar16. Turla MB, Thompson MM, Corjay MH, Owens GK. Mechanisms of angiotensin II- and arginine vasopressin-induced increases in protein synthesis and content in cultured rat aortic smooth muscle cells. Evidence for selective increases in smooth muscle isoactin expression.Circ Res. 1991; 68:288–299.LinkGoogle Scholar17. McDonald OG, Wamhoff BR, Hoofnagle MH, Owens GK. Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo.J Clin Invest. 2006; 116:36–48.CrossrefMedlineGoogle Scholar18. Yoshida T, Hoofnagle MH, Owens GK. Myocardin and Prx1 contribute to angiotensin II-induced expression of smooth muscle alpha-actin.Circ Res. 2004; 94:1075–1082.LinkGoogle Scholar19. Hoofnagle MH, Neppl RL, Berzin EL, Teg Pipes GC, Olson EN, Wamhoff BW, Somlyo AV, Owens GK. Myocardin is differentially required for the development of smooth muscle cells and cardiomyocytes.Am J Physiol Heart Circ Physiol. 2011; 300:H1707–H1721.CrossrefMedlineGoogle Scholar20. Merkel LA, Rivera LM, Colussi DJ, Perrone MH. Inhibition of EGF-induced vasoconstriction in isolated rabbit aortic rings with the tyrosine kinase inhibitor RG50864.Biochem Biophys Res Commun. 1993; 192:1319–1326.CrossrefMedlineGoogle Scholar21. Berk BC, Alexander RW, Brock TA, Gimbrone MA, Webb RC. Vasoconstriction: a new activity for platelet-derived growth factor.Science. 1986; 232:87–90.CrossrefMedlineGoogle Scholar22. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor.J Clin Invest. 1993; 91:94–98.CrossrefMedlineGoogle Scholar23. Tsuda T, Kawahara Y, Shii K, Koide M, Ishida Y, Yokoyama M. Vasoconstrictor-induced protein-tyrosine phosphorylation in cultured vascular smooth muscle cells.FEBS Lett. 1991; 285:44–48.CrossrefMedlineGoogle Scholar24. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.Circ Res. 1994; 74:1141–1148.LinkGoogle Scholar25. LeJemtel TH, Keung E, Frishman WH, Ribner HS, Sonnenblick EH. Hemodynamic effects of captopril in patients with severe chronic heart failure.Am J Cardiol. 1982; 49:1484–1488.CrossrefMedlineGoogle Scholar26. Ader R, Chatterjee K, Ports T, Brundage B, Hiramatsu B, Parmley W. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor.Circulation. 1980; 61:931–937.LinkGoogle Scholar27. Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).Am J Cardiol. 1988; 62:60A–66A.CrossrefMedlineGoogle Scholar28. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).Lancet. 2003; 362:782–788.CrossrefMedlineGoogle Scholar29. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, Boersma E. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients.Eur Heart J. 2012; 33:2088–2097.CrossrefMedlineGoogle Scholar30. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non–insulin-dependent diabetes mellitus: A 7-year follow-up study.Arch Intern Med. 1996; 156:286.CrossrefMedlineGoogle Scholar31. Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol. 2013; 62:e147–e239.CrossrefMedlineGoogle Scholar32. Mancia G, Fagard R, Narkiewicz K, Redan J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, List of authors Task Force. 2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the management of arterial hypertension.J Hypertens. 2013; 31:1925–1938.CrossrefMedlineGoogle Scholar33. Smith SC, Benjamin EJ, Bonow RO, et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.Circulation. 2011; 124:2458–2473.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Wolf P, Mohr A, Gavins G, Behr V, Mörl K, Seitz O and Beck‐Sickinger A (2021) Orthogonal Peptide‐Templated Labeling Elucidates Lateral ET A R/ET B R Proximity and Reveals Altered Downstream Signaling , ChemBioChem, 10.1002/cbic.202100340, 23:6, Online publication date: 18-Mar-2022. Manna V, Choi H, Rotoli S and Caradonna S (2022) The dynamic nature of the coronavirus receptor, angiotensin-converting enzyme 2 (ACE2) in differentiating airway epithelia, BBA Advances, 10.1016/j.bbadva.2022.100044, 2, (100044), . Poasakate A, Maneesai P, Potue P, Bunbupha S, Tong-Un T, Settheetham-Ishida W, Khamseekaew J and Pakdeechote P (2022) Genistein alleviates renin-angiotensin system mediated vascular and kidney alterations in renovascular hypertensive rats, Biomedicine & Pharmacotherapy, 10.1016/j.biopha.2021.112601, 146, (112601), Online publication date: 1-Feb-2022. Chandra S, Ehrlich K, Lacey M, Baribault C and Ehrlich M (2021) Epigenetics and expression of key genes associated with cardiac fibrosis: NLRP3, MMP2, MMP9, CCN2/CTGF and AGT , Epigenomics, 10.2217/epi-2020-0446, 13:3, (219-234), Online publication date: 1-Feb-2021. Cabbab I and Manalo R (2021) Anti-inflammatory drugs and the renin-angiotensin-aldosterone system: Current knowledge and potential effects on early SARS-CoV-2 infection, Virus Research, 10.1016/j.virusres.2020.198190, 291, (198190), Online publication date: 1-Jan-2021. Vessieres E, Guihot A, Grimaud L, Rivron J, Arnal J, Loufrani L and Henrion D (2020) Estrogens and the Angiotensin II Type 2 Receptor Control Flow-Mediated Outward Remodeling in the Female Mouse Mesenteric Artery, Journal of Vascular Research, 10.1159/000511799, 58:1, (16-26), . Stein R and Young L (2020) From ACE2 to COVID-19: A multiorgan endothelial disease, International Journal of Infectious Diseases, 10.1016/j.ijid.2020.08.083, 100, (425-430), Online publication date: 1-Nov-2020. Akintunde J, Akintola T, Adenuga G, Odugbemi Z, Adetoye R and Akintunde O (2020) Naringin attenuates Bisphenol-A mediated neurotoxicity in hypertensive rats by abrogation of cerebral nucleotide depletion, oxidative damage and neuroinflammation, NeuroToxicology, 10.1016/j.neuro.2020.08.001, 81, (18-33), Online publication date: 1-Dec-2020. Touyz R, Rios F, Alves-Lopes R, Neves K, Camargo L and Montezano A (2020) Oxidative Stress: A Unifying Paradigm in Hypertension, Canadian Journal of Cardiology, 10.1016/j.cjca.2020.02.081, 36:5, (659-670), Online publication date: 1-May-2020. Kilic A, Ustunova S, Usta C, Bulut H, Meral I, Demirci Tansel C and Gurel Gurevin E (2019) Angiotensin II type 2 receptor blocker PD123319 has more beneficial effects than losartan on ischemia–reperfusion injury and oxidative damage in isolated rat heart, Canadian Journal of Physiology and Pharmacology, 10.1139/cjpp-2019-0076, 97:12, (1124-1131), Online publication date: 1-Dec-2019. Wang D, Chai X, Magnussen C, Zosky G, Shu S, Wei X and Hu S (2019) Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation, Pulmonary Pharmacology & Therapeutics, 10.1016/j.pupt.2019.101833, 58, (101833), Online publication date: 1-Oct-2019. Medzikovic L, de Vries C and de Waard V (2019) NR4A nuclear receptors in cardiac remodeling and neurohormonal regulation, Trends in Cardiovascular Medicine, 10.1016/j.tcm.2018.11.015, 29:8, (429-437), Online publication date: 1-Nov-2019. MIRCHI L, CHYLÍKOVÁ B, JANKŮ M, ŠEDA O and LIŠKA F (2019) Transcriptomic Analysis of Left Ventricle Myocardium in an SHR Congenic Line With Ameliorated Cardiac Fibrosis, Physiological Research, 10.33549/physiolres.934127, (747-755), Online publication date: 21-Oct-2019. Eguchi S, Kawai T, Scalia R and Rizzo V (2018) Understanding Angiotensin II Type 1 Receptor Signaling in Vascular Pathophysiology, Hypertension, 71:5, (804-810), Online publication date: 1-May-2018. Nguyen T, Ding D, Wolter W, Champion M, Hesek D, Lee M, Pérez R, Schroeder V, Suckow M, Mobashery S and Chang M (2018) Expression of active matrix metalloproteinase-9 as a likely contributor to the clinical failure of aclerastide in treatment of diabetic foot ulcers, European Journal of Pharmacology, 10.1016/j.ejphar.2018.07.014, 834, (77-83), Online publication date: 1-Sep-2018. Forrester S, Booz G, Sigmund C, Coffman T, Kawai T, Rizzo V, Scalia R and Eguchi S (2018) Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology, Physiological Reviews, 10.1152/physrev.00038.2017, 98:3, (1627-1738), Online publication date: 1-Jul-2018. Chow B and Allen T (2016) Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease, Clinical Science, 10.1042/CS20160243, 130:15, (1307-1326), Online publication date: 1-Aug-2016. Heiat M, Najafi A, Ranjbar R, Latifi A and Rasaee M (2016) Computational approach to analyze isolated ssDNA aptamers against angiotensin II, Journal of Biotechnology, 10.1016/j.jbiotec.2016.05.021, 230, (34-39), Online publication date: 1-Jul-2016. Chang M (2016) Restructuring of the extracellular matrix in diabetic wounds and healing: A perspective, Pharmacological Research, 10.1016/j.phrs.2016.03.008, 107, (243-248), Online publication date: 1-May-2016. Caillon A, Grenier C, Grimaud L, Vessieres E, Guihot A, Blanchard S, Lelievre E, Chabbert M, Foucher E, Jeannin P, Beauvillain C, Abraham P, Loufrani L, Delneste Y and Henrion D (2016) The angiotensin II type 2 receptor activates flow-mediated outward remodelling through T cells-dependent interleukin-17 production, Cardiovascular Research, 10.1093/cvr/cvw172, 112:1, (515-525), Online publication date: 1-Oct-2016. Montezano A, Dulak-Lis M, Tsiropoulou S, Harvey A, Briones A and Touyz R (2015) Oxidative Stress and Human Hypertension: Vascular Mechanisms, Biomarkers, and Novel Therapies, Canadian Journal of Cardiology, 10.1016/j.cjca.2015.02.008, 31:5, (631-641), Online publication date: 1-May-2015. Lu L, Guo L, Xie T and Xin H (2015) Angiotensin converting enzyme is involved in the cardiac hypertrophy induced by sinoaortic denervation in rats, Cardiovascular Pathology, 10.1016/j.carpath.2014.08.006, 24:1, (41-48), Online publication date: 1-Jan-2015. Silva A, de Souza Silva L, Alves F, Der TorossianTorres M, de SáPinheiro A, Miranda A, LaraCapurro M and Oliveira V (2015) Effects of the angiotensin II Ala-scan analogs in erythrocytic cycle of Plasmodium falciparum (in vitro) and Plasmodium gallinaceum (ex vivo), Experimental Parasitology, 10.1016/j.exppara.2015.02.006, 153, (1-7), Online publication date: 1-Jun-2015. Balakumar P and Jagadeesh G (2014) Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor, Journal of Molecular Endocrinology, 10.1530/JME-14-0125, 53:2, (R71-R92), Online publication date: 4-Sep-2014. Verma K, Pant M, Paliwal S, Dwivedi J and Sharma S (2021) An Insight on Multicentric Signaling of Angiotensin II in Cardiovascular system: A Recent Update, Frontiers in Pharmacology, 10.3389/fphar.2021.734917, 12 Flores-Vergara R, Olmedo I, Aránguiz P, Riquelme J, Vivar R and Pedrozo Z (2021) Communication Between Cardiomyocytes and Fibroblasts During Cardiac Ischemia/Reperfusion and Remodeling: Roles of TGF-β, CTGF, the Renin Angiotensin Axis, and Non-coding RNA Molecules, Frontiers in Physiology, 10.3389/fphys.2021.716721, 12 Bento C, Gonçalves A, Silva B and Silva L (2020) Peach ( Prunus Persica ): Phytochemicals and Health Benefits , Food Reviews International, 10.1080/87559129.2020.1837861, (1-32) Bhullar S, Shah A and Dhalla N (2021) Role of angiotensin II in the development of subcellular remodeling in heart failure, Exploration of Medicine, 10.37349/emed.2021.00054, (352-371) Jones J, Nguyen T, Peng Z and Chang M (2019) Targeting MMP-9 in Diabetic Foot Ulcers, Pharmaceuticals, 10.3390/ph12020079, 12:2, (79) Vischer A, Kuster G, Twerenbold R, Pfister O, Zhou Q, Villiger A, Poglitsch M, Krähenbühl S, Mayr M, Osswald S, Haschke M and Burkard T (2021) Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients, Cells, 10.3390/cells10030534, 10:3, (534) Hennigs J, Matuszcak C, Trepel M and Körbelin J (2021) Vascular Endothelial Cells: Heterogeneity and Targeting Approaches, Cells, 10.3390/cells10102712, 10:10, (2712) Zhang H, Shao B, Dang Q, Chen Z, Zhou Q, Luo H, Yuan W and Sun Z (2021) Pathogenesis and Mechanism of Gastrointestinal Infection With COVID-19, Frontiers in Immunology, 10.3389/fimmu.2021.674074, 12 February 28, 2014Vol 114, Issue 5 Advertisement Article InformationMetrics © 2014 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.114.303045PMID: 24577962 Originally publishedFebruary 28, 2014 PDF download Advertisement SubjectsSmooth Muscle Proliferation and Differentiation
Referência(s)